GO:0002495 antigen processing and presentation of peptide antigen via MHC class II: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002495 describes the biological process by which an antigen-presenting cell expresses a peptide antigen on its surface in association with an MHC class II protein complex.
• MHC class II molecules are expressed primarily on professional antigen-presenting cells, including dendritic cells, macrophages, and B cells, and are essential for CD4+ T cell activation.
• The process involves antigen uptake, proteolytic processing, peptide loading onto MHC class II in endosomal compartments, and surface presentation to CD4+ T cells.
• Dysregulation of MHC class II antigen presentation contributes to autoimmune diseases, cancer immune evasion, and impaired responses to infection.
• Key genes include HLA-DRA, HLA-DRB1, CD74, and CIITA, which regulate antigen processing and presentation.
• CRISPR-based knockout, knock-in, and overexpression models enable functional dissection of MHC class II antigen presentation in health and disease.
Description
Antigen processing and presentation of peptide antigen via MHC class II (GO:0002495) is a central biological process in adaptive immunity. It enables antigen-presenting cells to display processed peptide antigens on their surface in association with MHC class II protein complexes, thereby activating CD4+ T cells. This process is critical for initiating and regulating immune responses against pathogens, tumors, and self-antigens. Understanding GO:0002495 is essential for researchers studying immunology, autoimmunity, cancer immunotherapy, and vaccine development. The pathway involves coordinated steps of antigen internalization, proteolytic degradation, peptide loading onto MHC class II molecules, and transport to the cell surface. Each step is tightly regulated by dedicated chaperones and accessory molecules, and defects in this pathway can lead to severe immunodeficiency or autoimmunity. This article provides a comprehensive overview of the molecular mechanisms, key genes, disease associations, and research methodologies related to GO:0002495.
antigen processing and presentation of peptide antigen via MHC class II At A Glance
| GO ID | GO:0002495 |
|---|---|
| GO term | antigen processing and presentation of peptide antigen via MHC class II |
| Ontology | biological_process |
| Synonym | peptide antigen processing and presentation via MHC class II |
| Major function | Presentation of processed peptide antigens on MHC class II molecules to CD4+ T cells |
| Cellular location | Endosomal compartments, lysosomes, plasma membrane |
| Key molecules | MHC class II (HLA-DR, HLA-DP, HLA-DQ), CD74 (invariant chain), HLA-DM, HLA-DO |
| Associated diseases | Autoimmunity, cancer immune evasion, immunodeficiency |
What Is GO:0002495?
GO:0002495, antigen processing and presentation of peptide antigen via MHC class II, is defined as the process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class II protein complex. The peptide antigen is typically, but not always, processed from a whole protein. This process is a subset of antigen processing and presentation and is specific to the MHC class II pathway, which primarily activates CD4+ T cells.
Why Is antigen processing and presentation of peptide antigen via MHC class II Important in Cell Biology?
GO:0002495 is fundamental to adaptive immunity because it governs the activation of CD4+ T helper cells, which orchestrate immune responses against extracellular pathogens, tumors, and allergens. Defects in this pathway can cause severe immunodeficiency or autoimmunity, and its dysregulation is a hallmark of cancer immune evasion. Moreover, MHC class II antigen presentation is critical for the efficacy of cancer immunotherapies and vaccines. Therefore, understanding the molecular details of this process is essential for developing therapeutic interventions.
• Essential for CD4+ T cell activation and adaptive immunity.
• Critical for defense against extracellular pathogens and viruses.
• Involved in autoimmune diseases such as alopecia areata and type 1 diabetes.
• Dysregulated in cancer, where tumor cells evade immune detection by suppressing MHC class II presentation.
• Required for effective cancer immunotherapy and vaccine responses.
• Regulated by the master transcription factor CIITA and cytokine signaling.
• MHC class II molecules are expressed on professional antigen-presenting cells and can be induced on other cell types.
• Ubiquitination of MHC class II molecules regulates their trafficking and function in B cells.
• Endothelial cells can present antigens via MHC class II to recruit and activate T cells.
• Mucosal viral infections elicit long-lived IgA responses via T follicular helper cells that depend on MHC class II presentation.
What Happens During antigen processing and presentation of peptide antigen via MHC class II?
Antigen Uptake and Internalization
In simple terms: The antigen-presenting cell takes in material from outside.
Antigen-presenting cells such as dendritic cells, macrophages, and B cells internalize extracellular antigens through phagocytosis, macropinocytosis, or receptor-mediated endocytosis. This step is essential for capturing pathogens and soluble proteins for subsequent processing. The internalized antigens are delivered to endosomal compartments where they are degraded.
Proteolytic Processing and Peptide Generation
In simple terms: The taken-in proteins are cut into small pieces called peptides.
Within endosomes and lysosomes, internalized antigens are proteolytically cleaved by acid-dependent proteases such as cathepsins. This generates peptide fragments of approximately 13-25 amino acids that can bind MHC class II molecules. The invariant chain (CD74) associates with MHC class II in the endoplasmic reticulum and protects the peptide-binding groove until it is removed in the endosomal compartment.
Peptide Loading onto MHC Class II
In simple terms: The peptide pieces are loaded onto special carrier molecules called MHC class II.
In late endosomes, the invariant chain is progressively degraded, leaving a class II-associated invariant chain peptide (CLIP) in the MHC class II groove. HLA-DM catalyzes the exchange of CLIP for high-affinity antigenic peptides. This loading process is tightly regulated and ensures that only stable peptide-MHC class II complexes are presented.
Surface Presentation and CD4+ T Cell Activation
In simple terms: The loaded MHC class II moves to the cell surface to show the peptide to T cells.
Peptide-loaded MHC class II complexes are transported to the plasma membrane via vesicular trafficking. There, they present the peptide antigen to CD4+ T cells through interaction with the T cell receptor. This interaction, together with co-stimulatory signals, leads to T cell activation, cytokine production, and proliferation. Ubiquitination of MHC class II molecules regulates their trafficking and surface levels in B cells.
Key Genes Involved in GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
The following genes encode proteins that are essential for antigen processing and presentation via MHC class II.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-DRA | MHC class II alpha chain; forms heterodimer with beta chain | Target for knockout to study antigen presentation |
| HLA-DRB1 | MHC class II beta chain; peptide binding and T cell recognition | Associated with autoimmune diseases; knockout models |
| CD74 | Invariant chain; chaperones MHC class II and blocks peptide binding | Knockout leads to defective MHC class II trafficking |
| HLA-DMA | HLA-DM alpha chain; catalyzes peptide exchange | Essential for peptide loading; knockout impairs presentation |
| HLA-DMB | HLA-DM beta chain; forms HLA-DM heterodimer | Regulates peptide editing |
| HLA-DOA | HLA-DO alpha chain; modulates HLA-DM function | Negative regulator of peptide loading |
| HLA-DOB | HLA-DO beta chain; forms HLA-DO heterodimer | Modulates HLA-DM activity in B cells |
| CIITA | Master transcription factor for MHC class II genes | Knockout abolishes MHC class II expression |
| RFX5 | Transcription factor; part of RFX complex | Mutations cause bare lymphocyte syndrome |
| RFXAP | Transcription factor; part of RFX complex | Required for CIITA-mediated activation |
| RFXANK | Transcription factor; part of RFX complex | Defects lead to immunodeficiency |
| CTSB | Cathepsin B; protease involved in antigen processing | Inhibitors or knockout affect peptide generation |
| CTSL | Cathepsin L; protease involved in invariant chain degradation | Knockout impairs MHC class II presentation |
| LAMP2 | Lysosomal-associated membrane protein 2; chaperone for MHC class II | Deficiency causes Danon disease with immune defects |
| CD4 | T cell co-receptor; binds MHC class II | Knockout abolishes CD4+ T cell responses |
| CD40 | Co-stimulatory molecule on antigen-presenting cells | Knockout impairs T cell activation |
| CD80 | Co-stimulatory ligand for CD28 | Overexpression enhances T cell activation |
| CD86 | Co-stimulatory ligand for CD28/CTLA-4 | Regulates T cell priming |
How Is antigen processing and presentation of peptide antigen via MHC class II Regulated?
The expression of MHC class II genes and the antigen presentation pathway are tightly regulated. The master transcription factor CIITA controls constitutive and interferon-gamma-inducible expression of MHC class II genes. Cytokines such as IFN-gamma upregulate CIITA, enhancing antigen presentation. Ubiquitination of MHC class II molecules by E3 ligases regulates their trafficking and surface turnover in B cells. Additionally, the invariant chain CD74 is regulated by inflammatory signals and can act as a receptor for MIF on CD4+ T cells. The process is also influenced by the cellular metabolic state and autophagy, which can deliver antigens to MHC class II compartments.
antigen processing and presentation of peptide antigen via MHC class II and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HLA-DRB1 | Rheumatoid arthritis, type 1 diabetes | Knock-in of risk alleles in mice |
| CIITA | Bare lymphocyte syndrome | Knockout in human cell lines |
| CD74 | Autoimmunity, cancer | Knockout mice and overexpression models |
| FAK (PTK2) | Pancreatic cancer immune evasion | Knockout in cancer cell lines |
| LAMP2 | Danon disease | Knockout iPSC-derived cardiomyocytes |
Autoimmune Diseases
Dysregulated MHC class II antigen presentation is a hallmark of autoimmune diseases. In alopecia areata, collapse of hair follicle immune privilege involves aberrant MHC class II expression and presentation of self-antigens. Genome-wide association studies have linked HLA-DR and HLA-DQ alleles to numerous autoimmune conditions, including type 1 diabetes, rheumatoid arthritis, and multiple sclerosis. The presentation of self-peptides by MHC class II to autoreactive CD4+ T cells triggers tissue destruction.
Cancer Immune Evasion
Tumors often downregulate MHC class II antigen presentation to evade CD4+ T cell surveillance. In pancreatic cancer, focal adhesion kinase (FAK) suppresses antigen processing and presentation, promoting immune evasion. Restoration of MHC class II expression or inhibition of FAK enhances anti-tumor immunity. Therefore, targeting the MHC class II pathway is a promising strategy for cancer immunotherapy.
Immunodeficiency
Mutations in genes required for MHC class II expression, such as CIITA, RFX5, RFXAP, and RFXANK, cause bare lymphocyte syndrome, a severe combined immunodeficiency characterized by absent MHC class II expression and defective CD4+ T cell responses. Patients suffer from recurrent infections and require bone marrow transplantation. This highlights the non-redundant role of GO:0002495 in human health.
Infectious Diseases
MHC class II antigen presentation is critical for protective immunity against viral and bacterial pathogens. Mucosal viral infection elicits long-lived IgA responses via type 1 follicular helper T cells that depend on MHC class II presentation. Pathogens such as Mycobacterium tuberculosis and Leishmania major manipulate MHC class II presentation to evade immune detection. Understanding these mechanisms can inform vaccine design.
From antigen processing and presentation of peptide antigen via MHC class II-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate MHC class II surface expression? | Knockout cell line (e.g., HeLa, HEK293T) followed by flow cytometry |
| Does a point mutation in HLA-DRB1 affect peptide binding? | Point mutation knock-in in antigen-presenting cells |
| Can overexpression of CIITA enhance antigen presentation? | Overexpression of CIITA in tumor cells |
| How does tagging MHC class II affect trafficking? | Knock-in of fluorescent tag (e.g., GFP) at HLA-DRA locus |
| What is the role of CD74 in antigen processing? | CD74 knockout mice or human cell lines |
| Does ubiquitination of MHC class II regulate B cell responses? | Knock-in of ubiquitin-deficient MHC class II mutants |
How to Study the antigen processing and presentation of peptide antigen via MHC class II Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface MHC class II and peptide-MHC complexes | Quantify presentation after gene knockout |
| Immunopeptidomics | Peptide sequences bound to MHC class II | Identify antigenic peptides for vaccines |
| CRISPR screen | Genes regulating MHC class II presentation | Discover novel pathway components |
| Confocal microscopy | Intracellular trafficking of MHC class II | Study endosomal loading and surface transport |
| Western blot | Protein expression of MHC class II subunits | Validate knockout efficiency |
| qPCR | mRNA levels of MHC class II genes | Assess transcriptional regulation |
| ELISPOT | Cytokine secretion by activated CD4+ T cells | Functional readout of antigen presentation |
Flow Cytometry
Flow cytometry is widely used to measure surface expression of MHC class II and peptide loading. Antibodies specific for HLA-DR, HLA-DP, HLA-DQ, or CLIP can quantify presentation levels on antigen-presenting cells. This method is rapid and quantitative, enabling high-throughput screening of genetic perturbations.
Immunoprecipitation and Mass Spectrometry
Immunoprecipitation of MHC class II molecules followed by mass spectrometry identifies the repertoire of bound peptides (immunopeptidomics). This approach reveals the specificity and diversity of presented antigens and is valuable for vaccine and immunotherapy development.
CRISPR Screens
Genome-wide CRISPR knockout screens can identify genes that regulate MHC class II antigen presentation. Cells are transduced with a sgRNA library, selected for MHC class II surface levels, and sequenced to identify enriched or depleted sgRNAs. This unbiased approach uncovers novel regulators of GO:0002495.
Live-Cell Imaging
Fluorescently tagged MHC class II and endosomal markers allow real-time visualization of vesicular trafficking and peptide loading in live cells. This method provides spatiotemporal insights into the dynamic process of antigen presentation.
How CRISPR Can Be Used to Study GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
Knockout
CRISPR knockout of genes such as HLA-DRA, CD74, or CIITA abolishes MHC class II antigen presentation, providing a clean background to study pathway requirements. Knockout cell lines are generated by introducing indels in early exons, followed by validation of protein loss and functional assays.
Point Mutation
Point mutations in MHC class II genes or accessory molecules can mimic human disease alleles. For example, introducing a single amino acid substitution in HLA-DRB1 that alters peptide binding allows researchers to dissect allele-specific effects on antigen presentation and T cell activation.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) or epitope tags at endogenous MHC class II loci enables tracking of protein trafficking and interaction partners in live cells. Knock-in of human HLA alleles into mouse models humanizes the immune system for translational studies.
Overexpression
Overexpression of CIITA or MHC class II subunits in tumor cells can restore antigen presentation and enhance anti-tumor immunity. This approach is used to study the sufficiency of individual genes in driving CD4+ T cell responses.
How EDITGENE Supports antigen processing and presentation of peptide antigen via MHC class II Research
Researchers studying antigen processing and presentation of peptide antigen via MHC class II-related genes often need to determine whether a candidate gene is causally involved in the pathway or merely correlated with its activity. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional interrogation of this pathway.
Contact EDITGENE today to design your custom CRISPR model for antigen processing and presentation of peptide antigen via MHC class II research.
Frequently Asked Questions About antigen processing and presentation of peptide antigen via MHC class II
What is antigen processing and presentation of peptide antigen via MHC class II?
It is the biological process (GO:0002495) by which antigen-presenting cells display processed peptide antigens on their surface using MHC class II molecules to activate CD4+ T cells.
What genes are involved in MHC class II antigen presentation?
Key genes include HLA-DRA, HLA-DRB1, CD74, HLA-DMA, HLA-DMB, CIITA, and cathepsins such as CTSB and CTSL.
Which cells perform antigen presentation via MHC class II?
Professional antigen-presenting cells, including dendritic cells, macrophages, and B cells, are the primary cells that present antigens via MHC class II.
How does MHC class II antigen presentation activate T cells?
Peptide-loaded MHC class II complexes on the cell surface interact with the T cell receptor on CD4+ T cells, leading to T cell activation, cytokine production, and proliferation.
What diseases are associated with defects in MHC class II antigen presentation?
Defects can cause bare lymphocyte syndrome (immunodeficiency), while dysregulation is linked to autoimmune diseases and cancer immune evasion.
How can I study MHC class II antigen presentation using CRISPR?
CRISPR knockout, knock-in, and overexpression models allow functional dissection of genes involved in the pathway. EDITGENE provides these services.
What is the role of CD74 in MHC class II antigen presentation?
CD74, also known as the invariant chain, chaperones MHC class II molecules and blocks the peptide-binding groove until it is removed in endosomes.
What is HLA-DM and what does it do?
HLA-DM is a catalyst that exchanges CLIP for high-affinity antigenic peptides on MHC class II molecules in endosomal compartments.
Can MHC class II antigen presentation be regulated?
Yes, it is regulated by the transcription factor CIITA, cytokines such as IFN-gamma, and ubiquitination of MHC class II molecules.
What methods are used to measure MHC class II antigen presentation?
Flow cytometry, immunopeptidomics, CRISPR screens, and imaging are commonly used to measure and study this process.
Conclusion
GO:0002495, antigen processing and presentation of peptide antigen via MHC class II, is a cornerstone of adaptive immunity. Its precise regulation is essential for defense against pathogens and for preventing autoimmunity and cancer. Advances in CRISPR-based models and high-throughput screening are accelerating our understanding of this pathway and enabling the development of novel immunotherapies. EDITGENE is committed to providing researchers with the tools needed to dissect this critical biological process.
References
- 1. Bertolini M et al.. 2020. Hair follicle immune privilege and its collapse in alopecia areata.. Exp Dermatol 29(8):703-725 PMID: 32682334
- 2. Helft J et al.. 2015. GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells.. Immunity 42(6):1197-211 PMID: 26084029
- 3. Zhang L et al.. 2024. CD74 is a functional MIF receptor on activated CD4(+) T cells.. Cell Mol Life Sci 81(1):296 PMID: 38992165
- 4. Haniuda K et al.. 2025. Mucosal viral infection elicits long-lived IgA responses via type 1 follicular helper T cells.. Cell 188(24):6774-6790.e21 PMID: 41253146
- 5. Canel M et al.. 2023. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer.. Gut 73(1):131-155 PMID: 36977556
- 6. Raymond M et al.. 2026. Ubiquitination of MHC class II molecules regulates B-cell development and response to antigens in mice.. J Immunol 215(1) PMID: 41218151
- 7. Ziegler PK et al.. 2018. Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis.. Cell 174(1):88-101.e16 PMID: 29909986
- 8. Cartura M et al.. 2026. Immunomodulatory endothelial cells contribute to T-cell recruitment and activation via antigen presentation on MHC II.. Cardiovasc Res 122(12):1672-1687 PMID: 42366791
